Parkinson's cell therapy progress and company context: a news update summarizing program developments, strategic partnerships, and longevity-sector implications.
Key Takeaways
- Kenai completed enrollment in the REPLACE Phase 1b/2a trial of RNDP-001
- RNDP-001 is an off-the-shelf allogeneic neuron replacement cell therapy targeting dopaminergic neurons
- RNDP-001 holds FDA Fast Track designation and initial safety observations will be reported